Cellectar Net Income from 2010 to 2026

CLRB Stock  USD 3.22  0.02  0.62%   
Cellectar Biosciences' Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -38.1 M this year. From 2010 to 2026 Cellectar Biosciences Net Loss quarterly data regression line had arithmetic mean of (18,927,289) and slope of (2,592,260). View All Fundamentals
 
Net Loss  
First Reported
2005-03-31
Previous Quarter
-5.4 M
Current Value
-4.4 M
Quarterly Volatility
4.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Cellectar Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectar Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 289 K, Interest Expense of 363.4 K or Total Revenue of 0.0, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.72 or Days Sales Outstanding of 741. Cellectar financial statements analysis is a perfect complement when working with Cellectar Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Cellectar Stock
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
Analyzing Cellectar Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Cellectar Biosciences's current valuation and future prospects.

Latest Cellectar Biosciences' Net Income Growth Pattern

Below is the plot of the Net Income of Cellectar Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cellectar Biosciences financial statement analysis. It represents the amount of money remaining after all of Cellectar Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cellectar Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectar Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (44.58 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Cellectar Net Income Regression Statistics

Arithmetic Mean(18,927,289)
Coefficient Of Variation(76.47)
Mean Deviation12,305,903
Median(13,562,290)
Standard Deviation14,472,942
Sample Variance209.5T
Range43.8M
R-Value(0.90)
Mean Square Error40.7T
R-Squared0.82
Slope(2,592,260)
Total Sum of Squares3351.5T

Cellectar Net Income History

2026-38.1 M
2025-40.1 M
2024-44.6 M
2023-42.8 M
2022-28.6 M
2021-24 M
2020-15.1 M

Other Fundumenentals of Cellectar Biosciences

Cellectar Biosciences Net Income component correlations

About Cellectar Biosciences Financial Statements

Cellectar Biosciences stakeholders use historical fundamental indicators, such as Cellectar Biosciences' Net Income, to determine how well the company is positioned to perform in the future. Although Cellectar Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectar Biosciences' assets and liabilities are reflected in the revenues and expenses on Cellectar Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectar Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-40.1 M-38.1 M
Net Loss-40.1 M-38.1 M
Net Loss-25.7 M-24.5 M
Net Loss(32.87)(34.51)
Net Income Per E B T 0.90  0.74 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. Projected growth potential of Cellectar fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cellectar Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(8.07)
Return On Assets
(0.72)
Return On Equity
(1.45)
Understanding Cellectar Biosciences requires distinguishing between market price and book value, where the latter reflects Cellectar's accounting equity. The concept of intrinsic value—what Cellectar Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cellectar Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Cellectar Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectar Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cellectar Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.